Quantcast

Latest ImmusanT Inc. Stories

2011-05-09 07:00:00

CHICAGO, May 9, 2011 /PRNewswire/ -- ImmusanT, Inc., a biotechnology company developing an immunotherapeutic vaccine, companion diagnostic and monitoring tool for celiac disease, reported positive results from a Phase 1 study evaluating the safety, tolerability and bioactivity of Nexvax2® in patients with celiac disease. ImmusanT Chief Scientific and Medical Officer Dr. Bob Anderson presented results from the Nexvax2 Phase 1 study and led a symposium and session...

2011-03-15 07:00:00

CAMBRIDGE, Mass., March 15, 2011 /PRNewswire/ -- Biotechnology company ImmusanT, Inc. today announced it has established its operations in Cambridge, Massachusetts and is advancing its strategy to develop an immunotherapeutic vaccine, companion diagnostic and monitoring tool for celiac disease. The company completed the acquisition of a discovery platform for targeted immunotherapies from Nexpep Pty., Ltd., based in Melbourne, Australia, and secured seed financing from angel investors to...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related